Literature DB >> 32094158

Antibody-mediated inhibition of syndecan-4 dimerisation reduces interleukin (IL)-1 receptor trafficking and signalling.

Lars Godmann1, Miriam Bollmann2, Adelheid Korb-Pap1, Ulrich König1, Joanna Sherwood1, Denise Beckmann1, Katja Mühlenberg1, Frank Echtermeyer3, James Whiteford4, Giulia De Rossi4, Thomas Pap5, Jessica Bertrand2.   

Abstract

OBJECTIVE: Syndecan-4 (sdc4) is a cell-anchored proteoglycan that consists of a transmembrane core protein and glucosaminoglycan (GAG) side chains. Binding of soluble factors to the GAG chains of sdc4 may result in the dimerisation of sdc4 and the initiation of downstream signalling cascades. However, the question of how sdc4 dimerisation and signalling affects the response of cells to inflammatory stimuli is unknown.
METHODS: Sdc4 immunostaining was performed on rheumatoid arthritis (RA) tissue sections. Interleukin (IL)-1 induced extracellular signal-regulated kinases (ERK) phosphorylation and matrix metalloproteinase-3 production was investigated. Il-1 binding to sdc4 was investigated using immunoprecipitation. IL-1 receptor (IL1R1) staining on wild-type, sdc4 and IL1R1 knockout fibroblasts was performed in fluorescence-activated cell sorting analyses. A blocking sdc4 antibody was used to investigate sdc4 dimerisation, IL1R1 expression and the histological paw destruction in the human tumour necrosis factor-alpha transgenic mouse.
RESULTS: We show that in fibroblasts, the loss of sdc4 or the antibody-mediated inhibition of sdc4 dimerisation reduces the cell surface expression of the IL-1R and regulates the sensitivity of fibroblasts to IL-1. We demonstrate that IL-1 directly binds to sdc4 and in an IL-1R-independent manner leads to its dimerisation. IL-1-induced dimerisation of sdc4 regulates caveolin vesicle-mediated trafficking of the IL1R1, which in turn determines the responsiveness to IL-1. Administration of antibodies (Ab) against the dimerisation domain of sdc4, thus, strongly reduces the expression IL1R1 on arthritic fibroblasts both in vitro and an animal model of human RA.
CONCLUSION: Collectively, our data suggest that Ab that specifically inhibit sdc4 dimerisation may support anti-IL-1 strategies in diseases such as inflammatory arthritis. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cytokines; fibroblasts; rheumatoid arthritis

Mesh:

Substances:

Year:  2020        PMID: 32094158     DOI: 10.1136/annrheumdis-2019-216847

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  6 in total

Review 1.  Emerging proteoglycans and proteoglycan-targeted therapies in rheumatoid arthritis.

Authors:  Brianna Hurysz; Nunzio Bottini
Journal:  Am J Physiol Cell Physiol       Date:  2022-04-27       Impact factor: 5.282

2.  Pathological Angiogenesis Requires Syndecan-4 for Efficient VEGFA-Induced VE-Cadherin Internalization.

Authors:  Giulia De Rossi; Maria Vähätupa; Enrico Cristante; Samantha Arokiasamy; Sidath E Liyanage; Ulrike May; Laura Pellinen; Hannele Uusitalo-Järvinen; James W Bainbridge; Tero A H Järvinen; James R Whiteford
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-02-18       Impact factor: 10.514

Review 3.  Syndecan-4 as a Pathogenesis Factor and Therapeutic Target in Cancer.

Authors:  Jessica Oyie Sousa Onyeisi; Carla Cristina Lopes; Martin Götte
Journal:  Biomolecules       Date:  2021-03-26

4.  A Reinterpretation of Evidence for the Endothelial Glycocalyx Filtration Structure.

Authors:  Kenton P Arkill
Journal:  Front Cell Dev Biol       Date:  2021-09-01

Review 5.  Synovial fibroblasts as potential drug targets in rheumatoid arthritis, where do we stand and where shall we go?

Authors:  Tamás Németh; György Nagy; Thomas Pap
Journal:  Ann Rheum Dis       Date:  2022-06-17       Impact factor: 27.973

6.  Comprehensive analysis of the expression of N6-methyladenosine RNA methylation regulators in pulmonary artery hypertension.

Authors:  Hao Zheng; Jing Hua; Hongpeng Li; Wenjuan He; Xiangyu Chen; Yingqun Ji; Qiang Li
Journal:  Front Genet       Date:  2022-09-12       Impact factor: 4.772

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.